NASDAQ:BMEA

Biomea Fusion (BMEA) Stock Forecast, Price & News

$38.24

+0.70 (+1.86%)

(As of 06/6/2023 ET)

Compare

Today's Range: $37.54
▼
$39.17
50-Day Range: $23.98
▼
$38.24
52-Week Range: $5.30
▼
$39.17

Volume: 1.14 million shs
Average Volume: 622,199 shs
Market Capitalization: $1.35 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $40.29

Biomea Fusion MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 5.3% Upside
$40.29 Price Target
Short Interest: Bearish
19.69% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: -0.04
Based on 5 Articles This Week
Insider Trading: Balanced
Insiders Both Buying and Selling
Proj. Earnings Growth: Decreasing
From ($3.54) to ($3.72) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.44 out of 5 stars

Medical Sector

911th out of 981 stocks

Pharmaceutical Preparations Industry

430th out of 460 stocks

2.5

Analyst's Opinion

Consensus Rating
Biomea Fusion has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $40.29, Biomea Fusion has a forecasted upside of 5.3% from its current price of $38.24.
Amount of Analyst Coverage
Biomea Fusion has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

1.0

Short Interest

Percentage of Shares Shorted
19.69% of the float of Biomea Fusion has been sold short.
Short Interest Ratio / Days to Cover
Biomea Fusion has a short interest ratio ("days to cover") of 6.8.
Change versus previous month
Short interest in Biomea Fusion has recently increased by 1.32%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Biomea Fusion does not currently pay a dividend.
Dividend Growth
Biomea Fusion does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for BMEA.

1.1

News and Social Media Coverage

News Sentiment
Biomea Fusion has a news sentiment score of -0.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for Biomea Fusion this week, compared to 3 articles on an average week.
Search Interest
Only 6 people have searched for BMEA on MarketBeat in the last 30 days. This is a decrease of -81% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Biomea Fusion to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Biomea Fusion insiders have sold just slightly more of their company's stock than they have bought. Specifically, they have bought $12,000,000.00 in company stock and sold $12,604,750.00 in company stock. It is common for insiders to sell company stock at intervals simply to diversify their holdings.
Percentage Held by Insiders
26.27% of the stock of Biomea Fusion is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
50.28% of the stock of Biomea Fusion is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Biomea Fusion are expected to decrease in the coming year, from ($3.54) to ($3.72) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Biomea Fusion is -11.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Biomea Fusion is -11.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Biomea Fusion has a P/B Ratio of 10.36. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Biomea Fusion (NASDAQ:BMEA) Stock

Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.

Receive BMEA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biomea Fusion and its competitors with MarketBeat's FREE daily newsletter.

BMEA Stock News Headlines

June 6, 2023 | benzinga.com

Biomea Fusion Unusual Options Activity For June 06

June 5, 2023 | americanbankingnews.com

Biomea Fusion, Inc. (NASDAQ:BMEA) Major Shareholder Sells $2,535,750.00 in Stock

June 7, 2023 | Behind the Markets (Ad)

Laser breakthrough could send stock soaring 2,467%

Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...

June 2, 2023 | fool.com

Biomea Fusion (NASDAQ: BMEA)

May 28, 2023 | seekingalpha.com

Biomea: Novel Approach To Diabetes And Cancer

May 23, 2023 | nasdaq.com

SGEN, ACAD & BMEA Drove Baker Brothers Advisors' Q1 Returns as ASND and HZNP Were Culled

May 22, 2023 | americanbankingnews.com

Biomea Fusion (NASDAQ:BMEA) Price Target Lowered to $53.00 at Citigroup

May 21, 2023 | americanbankingnews.com

Biomea Fusion, Inc. (NASDAQ:BMEA) Receives $40.57 Average Price Target from Analysts

June 7, 2023 | Legacy Research (Affiliate) (Ad)

The “Amazon Secret Royalty Program” Can Help Anyone Retire Like Royalty

A unique type of investment could help you make more money than you will need for the rest of your life. It’s what we call the “Amazon secret royalty program.” It’s an income stream that allows you to collect $1,000s… $10,000s… or more every year! Learn how to collect your first payout before June 13th.

May 18, 2023 | msn.com

Citigroup Maintains Biomea Fusion (BMEA) Buy Recommendation

May 12, 2023 | msn.com

Biomea Fusion Surges on New Buy Rating

May 12, 2023 | msn.com

Barclays Initiates Coverage of Biomea Fusion (BMEA) with Overweight Recommendation

May 12, 2023 | americanbankingnews.com

Biomea Fusion (NASDAQ:BMEA) Coverage Initiated at Barclays

May 12, 2023 | markets.businessinsider.com

Analysts Conflicted on These Healthcare Names: Biomea Fusion (BMEA) and Aveanna Healthcare Holdings (AVAH)

May 11, 2023 | americanbankingnews.com

Biomea Fusion, Inc. (NASDAQ:BMEA) Major Shareholder Sells $3,399,000.00 in Stock

May 8, 2023 | msn.com

Unusual Call Option Trade in Biomea Fusion (BMEA) Worth $686.20K

May 8, 2023 | markets.businessinsider.com

Piper Sandler Sticks to Their Buy Rating for Biomea Fusion (BMEA)

May 6, 2023 | finanznachrichten.de

Biomea Fusion, Inc.: Biomea Fusion Reports First Quarter 2023 Financial Results and Corporate Highlights

May 5, 2023 | americanbankingnews.com

HC Wainwright Comments on Biomea Fusion, Inc.'s Q2 2023 Earnings (NASDAQ:BMEA)

May 3, 2023 | msn.com

HC Wainwright & Co. Reiterates Biomea Fusion (BMEA) Buy Recommendation

May 2, 2023 | msn.com

Recap: Biomea Fusion Q1 Earnings

May 2, 2023 | finance.yahoo.com

Biomea Fusion Reports First Quarter 2023 Financial Results and Corporate Highlights

May 1, 2023 | marketwatch.com

Biomea Fusion Receives FDA Clearance for Leukemia Inhibitor's Investigational New Drug App

May 1, 2023 | finance.yahoo.com

Biomea Fusion Announces FDA Clearance of Investigational New Drug (IND) Application for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia

April 29, 2023 | americanbankingnews.com

Biomea Fusion, Inc. (NASDAQ:BMEA) Major Shareholder Sells $5,824,000.00 in Stock

April 28, 2023 | americanbankingnews.com

Biomea Fusion, Inc. (NASDAQ:BMEA) Receives $39.00 Consensus PT from Analysts

April 26, 2023 | seekingalpha.com

BMEA Biomea Fusion, Inc.

See More Headlines

BMEA Price History

30 days | 90 days | 365 days | Advanced Chart

BMEA Company Calendar

Last Earnings: 3/28/2023
Today: 6/06/2023
Next Earnings (Estimated): 8/07/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:BMEA
CUSIP: N/A
CIK: 1840439
Web: www.biomeafusion.com
Phone: 650-980-9099
Fax: N/A
Employees: 51
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $40.29
High Stock Price Forecast: $53.00
Low Stock Price Forecast: $22.00
Forecasted Upside/Downside: +6.0%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 7 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.21)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-81,830,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -79.98%
Return on Assets: -68.90%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.74
Quick Ratio: 4.74

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.69 per share
Price / Book: 10.30

Miscellaneous

Outstanding Shares: 35,400,000
Free Float: 26,100,000
Market Cap: $1.35 billion
Optionable: Not Optionable
Beta: -1.04

Key Executives

Mr. Thomas Andrew Butler (Age 41)
Co-Founder, Chairman & CEO
Comp: $772.86k

Mr. Ramses M. Erdtmann (Age 59)
Co-Founder, Pres, COO & Director
Comp: $570.57k

Mr. Franco Valle (Age 41)
CFO & Principal Accounting Officer
Comp: $251.69k

Mr. Heow Tan (Age 63)
Chief Technology & Quality Officer

Ms. Naomi Cretcher
Chief People Officer

Dr. Thorsten Kirschberg Ph.D. (Age 52)
Exec. VP of Chemistry

Dr. Stephan Morris M.D.
Chief Medical Officer

Mr. Ravi Upasani
Sr. VP of Intellectual Property

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

BMEA Stock - Frequently Asked Questions

Should I buy or sell Biomea Fusion stock right now?: 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Biomea Fusion in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BMEA shares.
View BMEA analyst ratings or view top-rated stocks.
What is Biomea Fusion's stock price forecast for 2023?: 7 equities research analysts have issued twelve-month price objectives for Biomea Fusion's stock. Their BMEA share price forecasts range from $22.00 to $53.00. On average, they predict the company's stock price to reach $40.29 in the next twelve months. This suggests a possible upside of 6.0% from the stock's current price.
View analysts price targets for BMEA or view top-rated stocks among Wall Street analysts.
How have BMEA shares performed in 2023?: Biomea Fusion's stock was trading at $8.43 at the beginning of 2023. Since then, BMEA shares have increased by 350.8% and is now trading at $38.00.
View the best growth stocks for 2023 here.
When is Biomea Fusion's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, August 7th 2023.
View our BMEA earnings forecast.
How were Biomea Fusion's earnings last quarter?: Biomea Fusion, Inc. (NASDAQ:BMEA) issued its earnings results on Tuesday, March, 28th. The company reported ($0.86) earnings per share for the quarter, missing analysts' consensus estimates of ($0.81) by $0.05.
What ETFs hold Biomea Fusion's stock?: ETFs with the largest weight of Biomea Fusion (NASDAQ:BMEA) stock in their portfolio include BlackRock Future Health ETF (BMED), Invesco Nasdaq Biotechnology ETF (IBBQ), iShares Biotechnology ETF (IBB), ProShares Ultra Nasdaq Biotechnology (BIB),

When did Biomea Fusion IPO?: (BMEA) raised $120 million in an initial public offering (IPO) on Friday, April 16th 2021. The company issued 7,500,000 shares at $15.00-$17.00 per share. J.P. Morgan, Jefferies and Piper Sandler served as the underwriters for the IPO.
What is Biomea Fusion's stock symbol?: Biomea Fusion trades on the NASDAQ under the ticker symbol "BMEA."
Who are Biomea Fusion's major shareholders?: Biomea Fusion's stock is owned by a number of retail and institutional investors. Top institutional shareholders include FMR LLC (7.57%), Baker BROS. Advisors LP (5.97%), BlackRock Inc. (2.78%), Perceptive Advisors LLC (0.92%), Geode Capital Management LLC (0.60%) and JPMorgan Chase & Co. (0.47%). Insiders that own company stock include A2a Pharmaceuticals, Inc, Bihua Chen, Franco Valle, Global Healthcare Ma Cormorant, Michael JM Hitchcock and Rainer M Erdtmann.
View institutional ownership trends.
How do I buy shares of Biomea Fusion?: Shares of BMEA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Biomea Fusion's stock price today?: One share of BMEA stock can currently be purchased for approximately $38.00.
How much money does Biomea Fusion make?: Biomea Fusion (NASDAQ:BMEA) has a market capitalization of $1.35 billion. The company earns $-81,830,000.00 in net income (profit) each year or ($3.21) on an earnings per share basis.
How can I contact Biomea Fusion?: The official website for the company is www.biomeafusion.com. The company can be reached via phone at 650-980-9099 or via email at vsandwick@biomeafusion.com.

This page (NASDAQ:BMEA) was last updated on 6/7/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial